MBL(Mannose binding lectine)-studie.

No registrations found.

Ethical review Positive opinion **Status** Recruiting

Health condition type -

Study type Observational non invasive

Summary

ID

NL-OMON24964

Source

Nationaal Trial Register

Health condition

Patients treated with chemotherapy for a solid tumor

Patienten die behandeling krijgen met chemotherapie vanwege een solide tumor

Sponsors and support

Primary sponsor: Sint Franciscus Gasthuis

Source(s) of monetary or material Support: Amgen, Roche

Intervention

Outcome measures

Primary outcome

Relation between baseline MBL and incidence of febrile neutropenia (FN).

Secondary outcome

- 1. MBL genotype and relation FN;
- 2. Changes in MBL concentration;

3. Relate severity of FN with MBL levels.

Study description

Background summary

Measuring MBL prior to chemotherapy and at an episode of FN in patients receiving chemotherapy for a solid tumor.

Study objective

MBL deficiency might give rise to a higher chance of the occurence of febrile neutropenia.

Study design

Prior to cycle 1 and prior to cycle 2 and during FN measurement of MBL.

Intervention

N/A

Contacts

Public

Sint Franciscus Gasthuis A.P. Hamberg Rotterdam 3045 PM The Netherlands +31 (0)10 4616145

Scientific

Sint Franciscus Gasthuis A.P. Hamberg Rotterdam 3045 PM The Netherlands +31 (0)10 4616145

Eligibility criteria

Inclusion criteria

- 1. Patients commencing chemotherapy treatments for a solid tumor;
- 2. Written informed consent.

Exclusion criteria

- 1. Previous participation in the current study;
- 2. Patients < 18 yrs;
- 3. Patients not able to give informed consent;
- 4. Patients receiving chemotherapy in a weekly schedule or a bi-weekly dose dense schedule;
- 5. Patients receiving granulocyte growth factor support (G-CSF);
- 6. Patients receiving a treatment with an individualized risk (combination of scheme and presence of risk factors) on FN over 20% according to the EORTC guidelines;
- 7. Patients receiving (prophylactic) antibiotics;
- 8. Patients receiving concomittant radiotherapy.

Study design

Design

Study type: Observational non invasive

Intervention model: Parallel

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

Recruitment

NI

Recruitment status: Recruiting

Start date (anticipated): 01-03-2012

Enrollment: 243

Type: Anticipated

Ethics review

Positive opinion

Date: 03-04-2012

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL3246 NTR-old NTR3398

Other SFG: 2011/42

ISRCTN wordt niet meer aangevraagd.

Study results

Summary results

N/A